SLC5A2 and cardiovascular disorder: The possible protective effects of ketone bodies on cardiovascular disease presently attract a great deal of interest because the EMPA-REG OUTCOME study recently demonstrated a remarkable effect of the SGLT2 inhibitor empagliflozin on cardiovascular and renal outcomes [13, 40].